Weight loss has consistently been associated with improved fertility.26 The use of tirzepatide and GLP1 receptor agonists has been associated with decreased GI absorption of oral contraceptive pills (OCPs), thus reducing their efficacy as contraceptives.27 Hence, women with obesity on tirzepatide should be encouraged to switch over to alternative methods of contraception, such as barrier methods, instead of OCPs. The gene discussed is GLP1R; the disease is obesity disorder.